Epistaxis clinical trials at UC Davis
1 research study open to eligible people
Tranexamic acid (promotes blood clotting) or placebo and direct pressure for treatment of nosebleeds in Emergency Department
“Can tranexamic acid reduce the duration of a nosebleed?”
open to eligible people ages 18 years and up
It is estimated that epistaxis results in 4.5 million emergency department visits per year throughout the United States. Due to the adverse effects of standard treatment options for epistaxis, tranexamic acid (TXA) may be considered an attractive option. In previous studies, when used with nasal packing, TXA showed faster time to control of bleeding. The goal of this study is to determine the efficacy and safety of topical intranasal TXA applied via atomizer for patients with epistaxis who present to the emergency department.